Johnson & Johnson Announces Acquisition of Atraverse Medical to Complete Electrophysiology Portfolio with Hotwire Transseptal Access System

On April 24, Johnson & Johnson officially announced withInnovative HealthcareMedical Device Company Atraverse Medical Signs Definitive Acquisition Agreement to Integrate the Latter into Its Medical Technology Division.

Data shows that Atraverse Medical is an innovative enterprise focused on the research and development of cardiac interventional access devices.Co-founded by Steven Mickelsen, known as the "Father of PFA," alongside Eric Sauter and John Slump., whose core product, the Hotwire Transseptal Access System, has been applied in nearly 3,000 clinical surgeries.

From an industry perspective, this acquisition is not only another precise layout by Johnson & Johnson in the cardiac ablation field, but also reflects the deep logic of global medical technology giants building full-industry-chain barriers and seizing high-growth tracks through mergers and acquisitions. It is reported that this acquisition is expected to be completed in the second quarter of 2026, with specific financial terms yet to be disclosed.

01

Another Major Acquisition

Complete the Full Chain of Electrophysiology

The core value of this acquisition lies in filling a critical "pathway link" for Johnson & Johnson's existing cardiac ablation solutions.Achieving a complete clinical closed loop from mapping, access establishment to ablation treatment。

According to the official announcement from Johnson & Johnson, Atraverse Medical is headquartered in San Diego, USA, and its core product is Hotwire.Transseptal Access System, an innovative left-heart interventional device integrating a radiofrequency guidewire and a radiofrequency generator, is specifically designed for minimally invasive ablation procedures for atrial fibrillation and other arrhythmias.

Currently, the system has received dual FDA certification: In May 2024, the Hotwire RF guidewire was first approved; in December 2025, the accompanying RF generator completed its second certification, marking the full commercial rollout of the system. As of the release of the acquisition announcement, the Hotwire system had been successfully applied in over 3,000 clinical surgeries worldwide, with positive clinical data performance.

In atrial fibrillation ablation procedures, safely and accurately establishing access to the left atrium is a core factor that determines the success and efficiency of the surgery, as well as a long-standing pain point in clinical practice. Traditional transseptal puncture relies on step-by-step operations using a puncture needle and guidewire, which presents issues such as cumbersome instrument changes, imprecise energy control, and higher puncture risks.

The core breakthrough of the Hotwire system lies inZero-instrument Exchange Left Heart Access Establishment: Guidewire Can Directly Complete Puncture and Serve as the Operational Track for Subsequent Catheter Treatment, Greatly Simplifying the Surgical Process。

For Johnson & Johnson, the acquisition of Atraverse is not merely a simple product addition but a strategically precise move to fill a gap. Currently, Johnson & Johnson Medical Technologies already possesses two core electrophysiology assets: the Carto 3 three-dimensional mapping system and the Varipulse pulsed field ablation platform, which respectively dominate the critical stages of cardiac mapping and ablation therapy.

The integration of the Hotwire system will fully connect the entire process chain of mapping, access, and ablation, giving Johnson & Johnson a closed-loop advantage in the globally high-growth field of atrial fibrillation ablation. As officially stated by Johnson & Johnson Medical Technologies, this acquisition will "further strengthen its cardiac ablation solutions portfolio" and solidify its leadership position in the electrophysiology field.

02

Focus on Electrophysiology

The acquired party was founded by the "Father of PFA"

As the acquired party in this transaction, Atraverse Medical's core competitiveness also lies in its team's deep accumulation and successful entrepreneurial experience in the field of cardiac electrophysiology.

It is reported that Atraverse Medical was founded in July 2022, and its founding team is considered a "star lineup" in the field of cardiac electrophysiology. The company was co-founded by Steven Mickelsen, Eric Sauter, and John Slump. Among them, Steven Mickelsen is a pioneer in the field of pulsed field ablation (PFA) and is known as the "Father of PFA."Previously, the Farapulse company he co-founded with Eric Sauter was acquired by Boston Scientific for up to 800 million US dollars in 2021, becoming a classic M&A case in the electrophysiology field.。

CEO John Slump, a serial entrepreneur with three medical technology company acquisition exits under his belt and cumulative transaction value exceeding $1 billion, demonstrates mature commercialization and team management capabilities. This team, which successfully developed and commercialized PFA technology, has once again focused on the clinical pain point of transseptal access. They propelled the Hotwire system to achieve FDA approval in just 22 months, showcasing exceptional technical translation and clinical implementation abilities.

From the perspective of product layout, Atraverse Medical adopts a strategy of single-point breakthrough and deep cultivation, focusing on the niche track of trans-septal access devices without pursuing diversified expansion. Since its establishment, all R&D resources have been devoted to the iterative optimization of the Hotwire system, from guidewire design, RF generator integration to clinical validation, forming a complete technical barrier.

In June 2025, Atraverse completed a $29.4 million Series A financing round led by Mohan Growth Partners. The funds were primarily used for the global commercial promotion and clinical data accumulation of the Hotwire system. Prior to its acquisition, the company had established collaborations with multiple top cardiac centers worldwide. The clinical data, covering multicenter and multi-procedural cases, validated the safety and efficacy of the Hotwire system, laying a solid foundation for its subsequent integration into Johnson & Johnson's commercial system.

Some viewpoints indicate that Atraverse Medical, with its three core values of technology, team, and clinical validation, aligns closely with Johnson & Johnson Medical Technologies' M&A preference for "focusing on highly innovative and high-growth early-stage targets," which has become a key reason for the swift completion of this transaction.

03

Johnson & Johnson's Dual-Track M&A Strategy

Build a Full Cardiovascular Industry Chain

It is worth mentioning that,One of the most active acquirers in the global medical device industry, Johnson & JohnsonMedical TechnologySince focusing on core sectors and divesting its consumer health business in 2022,More than 30 billion US dollars have been invested in the medical field.Therapy Technology M&A. Among them,The cardiovascular field has become one of the key focuses of its mergers and acquisitions.

From the perspective of M&A strategy, Johnson & Johnson's acquisitions follow a dual-track model of major strategic purchases and early-stage innovative enhancements, with a core focus on the high-growth cardiovascular sector. In terms of significant acquisitions, in 2022, it spent $16.6 billion to acquire Abiomed, filling the gap in severe heart failure. In 2024, it acquired Shockwave Medical for $13.1 billion to enter the vascular calcification treatment field, while also purchasing companies like V-Wave and Laminar to further enhance its product pipeline.

As a startup founded just four years ago, Atraverse is a prime example of early-stage innovative reinforcement. Its technological innovation and strategic synergy are extremely strong, aligning with Johnson & Johnson's reinforcement-focused M&A strategy to quickly address gaps in its product portfolio.

Previously, Johnson & Johnson Medical Technology stated that all its merger and acquisition decisions must meet three core criteria: scientific alignment, strategic alignment, and financial alignment. This logic was fully reflected in the acquisition of Atraverse Medical, Inc.

Today, Johnson & Johnson has built a comprehensive cardiovascular industry chain layout—from electrophysiology to heart failure, vascular calcification, and structural heart disease—through a series of acquisitions. It now forms a "Big Four" competitive landscape alongside Medtronic, Abbott, and Boston Scientific. In the electrophysiology sector, which boasts an annual growth rate exceeding 15%, Johnson & Johnson has established a significant leading advantage with its closed-loop solutions, continuously reshaping the competitive landscape of the global cardiovascular medical device industry.

Looking at the global trend of the medical device industry development,The competition in the cardiovascular intervention sector has evolved from a single-product contest toComprehensive Solutions and Clinical Full-Process EcosystemThe Comprehensive Competition PhaseJohnson & Johnson's acquisition of Atraverse Medical is not only a single tactical enhancement but also the implementation of a long-term strategy by the giant to leverage its mature M&A system to deeply cultivate niche fields and build technological barriers.

Against the backdrop of accelerating industry consolidation, continuous upgrading of clinical needs, and faster iteration of innovative technologies, international medical device companies represented by Johnson & Johnson are refining their M&A strategies to precisely address unmet clinical pain points. Relying on both in-house research and acquisitions as dual drivers, they are continuously optimizing their pipeline layouts.

In the field of cardiac electrophysiology, the left heart approach, as a key component of ablation procedures, will drive the standardization and minimally invasive advancements in the industry through its technological upgrades. With its financial strength, distribution channels, clinical resources, and mature integration capabilities, Johnson & Johnson is well-positioned to leverage the Hotwire system for synergistic product expansion.